EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications

Kristina H Lewis iD, Fang Zhang, Robert F LeCates, Stephanie Argetsinger, Stefanie Albert, Geetha S Iyer, John G Connolly, James F Wharam, David E Arterburn iD, Dennis Ross-Degnan, Sengwee Toh

Obesity · 2026-06 · 34 (6) · 1331-1342

DOI: 10.1002/oby.70208 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Obesity, online erschienen am 12.05.2026. Verfasst von Kristina H Lewis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology & Prevention, Department of Implementation Science, Division of Public Health Sciences, Wake Forest University Health Scie…. Hauptthemen laut MEDLINE: Obesity, Health Care Costs, Anti-Obesity Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs).

Methods

Commercial insurance claims were used to identify new initiators of phentermine ( n = 136,788), phentermine‐topiramate‐ER ( n = 13,888), naltrexone‐bupropion‐SR ( n = 28,712), or liraglutide ( n = 49,266) for obesity. Multivariable difference‐in‐differences analyses compared the three newer drugs to phentermine for change in total annual prescription drug and health care costs, outpatient visits, and acute care use (combined emergency department visits and hospital stays).

Results

Up to 3 years after OM initiation, prescription and total health care costs were higher for all three newer OM cohorts relative to phentermine, with liraglutide having the greatest comparative increase in annual costs (e.g., total costs 73.6% [70.9%, 76.3%] higher in year 1). Primary care physician visit frequency was slightly lower for the newer OMs (e.g., −12.6% [−13.6%, −11.6%] in year 1 for liraglutide).

Conclusions

The cost of OM treatment, even for medications that preceded highly effective weekly incretin analogues, appeared to increase overall prescription spending and total health care costs. Yet, other than a relative decrease in primary care physician visit frequency, more costly OMs were not associated with favorable changes in health care use patterns compared to generic phentermine. Reductions in OM cost and other interventions to support their longer‐term use may be needed to fully realize the promise of these medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityHealth Care CostsAnti-Obesity AgentsHumansLiraglutideNaltrexoneFemaleMalePhentermineBupropionMiddle AgedAdultTopiramateEmergency Room Visits

Stichwörter der Autor:innen

health care costliraglutidenaltrexone‐bupropion‐SRobesity medicationphenterminephentermine‐topiramate‐ER

Substanzen

LiraglutideNaltrexoneAnti-Obesity AgentsPhentermineBupropionTopiramate

Autor:innen und Institutionen

  • Department of Epidemiology & Prevention, Department of Implementation Science, Division of Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Duke University, Durham, North Carolina, USA.
  • Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
  • Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

ORCID-Profile: Kristina H Lewis, David E Arterburn

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Lewis, K. H., Zhang, F., LeCates, R. F., Argetsinger, S., Albert, S., Iyer, G. S., Connolly, J. G., Wharam, J. F., Arterburn, D. E., Ross-Degnan, D., & Toh, S. (2026). Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications. Obesity, 34(6), 1331-1342. https://doi.org/10.1002/oby.70208

Vancouver

Lewis KH, Zhang F, LeCates RF, Argetsinger S, Albert S, Iyer GS, et al. Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications. Obesity. 2026;34(6):1331-1342. doi:10.1002/oby.70208

BibTeX
@article{Lewis2026,
  author = {Lewis, Kristina H and Zhang, Fang and LeCates, Robert F and Argetsinger, Stephanie and Albert, Stefanie and Iyer, Geetha S and Connolly, John G and Wharam, James F and Arterburn, David E and Ross-Degnan, Dennis and Toh, Sengwee},
  title = {Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1331--1342},
  doi = {10.1002/oby.70208}
}
Kostenlos starten →